Literature DB >> 12545079

HIV RNA in plasma rebounds within days during structured treatment interruptions.

Marek Fischer1, Roland Hafner, Christine Schneider, Alexandra Trkola, Beda Joos, Helen Joller, Bernard Hirschel, Rainer Weber, Huldrych F Günthard.   

Abstract

OBJECTIVE: To evaluate time to viral rebound in patients undergoing repeated structured treatment interruptions (STI).
METHOD: Fourteen chronically HIV-infected patients enrolled in the Swiss-Spanish Intermittent Treatment Trial (SSITT) underwent frequent blood sampling. Patients underwent four cycles of 2-week STI, followed by 8-week retreatment with the identical antiretroviral treatment (HAART) used before STI. At the fifth cycle, treatment was stopped for a longer period. Before each new STI, plasma viral load (VL) had to reach < 50 copies/ml. VL was measured during day 0 (last day on HAART) and on days 4, 8 and 14 during all five STI.
RESULTS: During the first cycle, plasma HIV RNA increased to > 50 copies/ml (range, 67-88) in five patients at day 4, in eight patients (> 100 copies/ml) at day 8 and in 12 patients (> 100 copies/ml) at day 14. Cumulative analysis of the frequency of detectable HIV RNA at days 4, 8 and 14 compared with day 0 for all five cycles revealed nine patients with VL > 50 copies/ml [13 of 54 samples tested (24.1%); = 0.14] at day 4, 11 patients [33 of 58 samples tested (56.9%); < 0.0001] at day 8 and 12 patients [53 of 65 samples tested (81.5%); < 0.0001] at day 14.
CONCLUSIONS: Significant viral replication can be induced during 1 week STI, and this may increase the risk of the emergence of drug resistance during long-term cycling. Therefore, short-term cycling strategies such as 1-week-on, 1-week-off treatment, although conceptually intriguing, should still be regarded as investigational and should be restricted to rigorously controlled clinical trials ideally involving patients who have never failed treatment before.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12545079     DOI: 10.1097/00002030-200301240-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  30 in total

1.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

Review 2.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

3.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

4.  The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Authors:  Paula Lerner; Moraima Guadalupe; Richard Donovan; Jason Hung; Jason Flamm; Thomas Prindiville; Sumathi Sankaran-Walters; Michael Syvanen; Joseph K Wong; Michael D George; Satya Dandekar
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway.

Authors:  Young Kyeung Kim; Uri Mbonye; Joseph Hokello; Jonathan Karn
Journal:  J Mol Biol       Date:  2011-07-29       Impact factor: 5.469

6.  HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.

Authors:  Gideon Goldstein; Eve Damiano; Mardik Donikyan; Malika Pasha; Erik Beckwith; John Chicca
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

7.  Host and viral genetic correlates of clinical definitions of HIV-1 disease progression.

Authors:  Concepción Casado; Sara Colombo; Andri Rauch; Raquel Martínez; Huldrych F Günthard; Soledad Garcia; Carmen Rodríguez; Jorge Del Romero; Amalio Telenti; Cecilio López-Galíndez
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

8.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

9.  Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells.

Authors:  Sona Budhiraja; Marylinda Famiglietti; Alberto Bosque; Vicente Planelles; Andrew P Rice
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 10.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.